Bosh sahifaIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
Yopilish kursi
34,10Â $
Kunlik diapazon
33,15Â $ - 33,77Â $
Yillik diapazon
33,15Â $ - 54,44Â $
Bozor kapitalizatsiyasi
5,28Â mlrd USD
Oʻrtacha hajm
1,46Â mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 133,81Â mln | -7,21% |
Joriy xarajat | 259,28Â mln | -2,73% |
Sof foyda | -140,48Â mln | 4,70% |
Sof foyda marjasi | -104,98 | -2,70% |
Har bir ulushga tushum | -0,72 | 14,35% |
EBITDA | -145,68Â mln | -3,99% |
Amaldagi soliq stavkasi | 2,51% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 2,49Â mlrd | 11,10% |
Jami aktivlari | 3,08Â mlrd | 5,01% |
Jami passivlari | 2,42Â mlrd | -7,63% |
Umumiy kapital | 662,47 mln | — |
Tarqatilgan aksiyalar | 157,90 mln | — |
Narxi/balansdagi bahosi | 8,12 | — |
Aktivlardan daromad | -12,88% | — |
Kapitaldan daromad | -15,15% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -140,48Â mln | 4,70% |
Operatsiyalardan naqd pul | -114,99Â mln | -5,47% |
Sarmoyadan naqd pul | -340,80Â mln | -595,98% |
Moliyadan naqd pul | 496,05Â mln | 1Â 637,32% |
Naqd pulning sof oʻzgarishi | 40,61 mln | 155,84% |
Boʻsh pul | -46,15 mln | 46,55% |
Haqida
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Tashkil etilgan
1989
Sayt
Xodimlar soni
927
